Guardant Health just unveiled nearly a dozen new capabilities for its Guardant360® Liquid blood test—turning a routine draw into a powerful tool for cancer profiling. Using AI and multiomic analysis, the test can now determine tumor origin, subtype, and even drug compatibility—all without needing tissue. For colorectal cancer, the test can confirm the absence of actionable mutations, helping doctors skip additional tests and begin treatment faster. It also identifies key biomarkers, including those tied to HPV and EBV, and assesses pharmacogenomic safety for common therapies.
Author: Rutali Thakur
Screening for colorectal cancer just got radically easier. New Day Diagnostics has launched ColoHealth™, a first-of-its-kind blood test available direct-to-consumer—no bowel prep, no anesthesia, no day off work. It’s already turning heads with one powerful stat: over 99% of people who previously avoided traditional screening went through with this test. With a sensitivity of 73.3% and a negative predictive value of 99.8%, ColoHealth™ doesn’t just offer convenience—it delivers clinical credibility. It detects nearly twice as many precancers as earlier blood-based options, offering a critical window for early intervention.
Biomerica (NASDAQ: BMRA) reported significant real-world data for its inFoods® IBS diagnostic-guided therapy, showing remarkable symptom reduction in IBS patients. Data from over 360 patients demonstrated a 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period. The company also launched a HIPAA-compliant real-time patient feedback system that enables physicians to track symptoms and adjust treatment plans accordingly. These results complement a peer-reviewed study published in Gastroenterology, which showed that patients on an inFoods® IBS-guided diet experienced significantly more abdominal pain relief compared to placebo (59.6% vs. 42.1%, p-value=0.02).
PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that identifies genetic variants associated with cancer risk to help cancer care teams provide optimal patient care. Germline genetic testing is recommended by medical practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention.1 The testing analyzes inherited genetic variants, typically present in all the cells of the body, that may predispose an individual to certain risks or diagnoses, including hereditary…
At Google I/O 2025, Google introduced MedGemma, a powerful suite of open-source AI models built on the Gemma 3 architecture, designed to advance multimodal medical understanding. The suite includes MedGemma 4B, a 4-billion parameter model for joint image-text tasks like interpreting chest X-rays or dermatology scans, and MedGemma 27B, a text-only model tuned for deep clinical reasoning and advanced medical text analysis. These models are accessible via Hugging Face and deployable through Google Cloud’s Vertex AI for production use. Optimized for tasks such as diagnostic support, triage, and medical report generation, MedGemma is also fine-tunable using methods like LoRA or…
Effective colorectal cancer (CRC) prevention hinges on high-level detection during colonoscopy. This requires thorough knowledge of subtle precancerous lesion appearances, optimal bowel preparation, use of high-definition scopes, and consistent tracking of adenoma detection rates. The whitepaper outlines updated recommendations, common detection barriers, and emerging tools and techniques to enhance visualization and improve lesion detection performance.
Despite heightened federal and state scrutiny, policy responses to private equity (PE) in healthcare remain limited. The authors argue that while PE ownership has undeniably surged across hospitals, physician practices, and outpatient services—often leading to higher prices and concerns about quality—there’s a gap between political outrage and concrete regulatory action. Authors Barak Richman and Richard Scheffler urge a shift from generalized blame to targeted policy grounded in a deeper understanding of PE’s organizational strategies. They call for evidence-based regulation that distinguishes harmful behaviors from the structure of ownership, warning that outrage alone won’t fix systemic vulnerabilities in healthcare markets.
Novel Device Shown to Dramatically Improve Scope Stability and Control for Gastroenterologists of All Skill Levels BURLINGAME, Calif.–(BUSINESS WIRE)–Neptune Medical, a leader in medical device innovation, today announced positive new data from two studies presented at the prestigious Digestive Disease Week conference demonstrating that its Pathfinder Endoscope Overtube significantly improves endoscope control and completion of difficult upper and lower endoscopic procedures.
In a first-in-human Phase 1 trial, researchers from the University of Minnesota used CRISPR/Cas9 gene-editing technology to modify tumor-infiltrating lymphocytes (TILs) in patients with advanced gastrointestinal (GI) cancers, particularly metastatic colorectal cancer. The team knocked out a gene called CISH, which acts as an internal checkpoint limiting T cell effectiveness. Disabling this gene enhanced the immune cells’ ability to recognize and attack tumors. Twelve late-stage patients were treated with over 10 billion gene-edited T cells, with no major safety concerns. Several showed disease stabilization, and notably, one patient achieved a complete response, with cancer disappearing and remaining undetectable for over…
In this Perspective article, Drs. Chen and Murthy argue that the current sociopolitical climate in the U.S. poses serious threats to public health, physician autonomy, and core healthcare values. They emphasize that the challenges facing the nation go beyond partisan politics and touch on the well-being of patients and the integrity of the medical profession.